Recruiting NCT06178822

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Trial Parameters

Condition Sepsis

Sponsor Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)

Study Type OBSERVATIONAL

Phase N/A

Enrollment 3,300

Sex ALL

Min Age 18 Years

Max Age N/A

Start Date 2022-10-25

Completion 2026-10-01

All Conditions

Sepsis Septic Shock Sepsis, Severe Infections Infection Viral Infection, Bacterial Infections, Respiratory

Interventions

No intervention

Brief Summary

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or higher * Presentation at the Emergency Department (ED) * Clinical suspicion of infection or earlier confirmed infection * Modified Early Warning Score (MEWS) of 2 or higher Exclusion Criteria: * No informed consent given

Related Trials

NCT07040202

Immune Responses to Dengue and Sepsis

View Trial →

NCT02979951

Fosfomycin I.v. for Treatment of Severely Infected Patients

View Trial →

NCT06694181

Safe and Explainable AI

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE SEPSIS TRIALS